Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

Indication: Oligometastases (1-5) in castration-resistant prostate carcinoma Inclusion Criteria: * Patient with good general condition (WHO 0-1) * Histologically confirmed prostate carcinoma * After definitive local therapy, e.g. radical prostatectomy or definitive radiotherapy (also after neo-adjuvant hormone therapy, after postoperative radiotherapy). * PSA progression under ongoing androgen deprivation (defined as three consecutive increasing PSA values at intervals of \> 4 weeks and testosterone in the castration area \<50ng/dl or \<1.73nmol/) * Minimum duration of androgen deprivation 6 months before inclusion in study * Present complete staging (max. 6 weeks old), preferably by means of PET hybrid imaging with prostate-specific PET tracer * Imaging detection of individual active or progressive metastases (max. 5, depending on location) that are accessible to local ablative radiotherapy (histological confirmation of the metastases is not required) * No parallel participation to further clinical therapy trials up to 4 weeks before and after radiation therapy * Individual case discussion in an interdisciplinary tumor board * Patient's ability to consent and written consent Exclusion Criteria: * Severe concomitant disease that limits further life expectancy to \< 5 years according to the physician's assessment. * PSA \> 20ng/ml, testosterone \>50 dl or \>1,73nmol/l * visceral metastasis (e.g. lung, liver, brain) * lack of compliance * previous taxane-containing chemotherapy